Novelion Therapeutics (Novelion Therapeutics) GF Score : 0/100 (As of May. 22, 2024)

View and export this data going back to 1988. Start your Free Trial

What is Novelion Therapeutics GF Score?

Novelion Therapeutics has the GF Score of 0, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 0/10
2. Profitability Rank : 0/10
3. Growth Rank : 0/10
4. GF Value Rank : 0/10
5. Momentum Rank : 0/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Novelion Therapeutics might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Novelion Therapeutics (OTCPK:NVLNF) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score	Performance Potential and All-in-One Screener Examples ⁽¹⁾
91 - 100	Highest outperformance potential
81 - 90	Good outperformance potential
71 - 80	Likely to have average performance
51 - 70	Poor future performance potential
0 - 50	Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Novelion Therapeutics GF Score Related Terms

Thank you for viewing the detailed overview of Novelion Therapeutics's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Novelion Therapeutics (Novelion Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novelion Therapeutics Inc (OTCPK:NVLNF) » Definitions » GF Score

Comparable Companies

Traded in Other Exchanges

N/A

Address

c/o Norton Rose Fulbright, 1800 West Georgia Street, Suite 510, Vancouver, BC, CAN, V6B 0M3

Website

http://www.novelion.com

Headquartered in Vancouver, Canada, QLT is a biotechnology company that researches and develops products used to treat conditions of the eye. After a recent board change, QLT divested its only marketed product, a laser treatment called Visudyne for the treatment of wet age-related macular degeneration and subfoveal choroidal neovascularization. QLT also earns royalty payments on other certain previously divested products. Following recent pipeline changes, the company currently has one product in development for two rare eye conditions.

Executives

Kevin Kotler	10 percent owner	C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Capital, Llc	10 percent owner	300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Healthcare Master Fund Ltd	10 percent owner	C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108
Stonepine Capital, L.p.	10 percent owner	919 NW BOND STREET, SUITE 204, BEND OR 97703
Michael Dennis Price	officer: Chief Financial Officer
Benjamin Harshbarger	officer: See Remarks	ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142
Mark Dipaolo	director	660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
John J Orloff	director	C/O BAXALTA INCORPORATED 1200 LAKESIDE DRIVE BANNOCKBURN IL 60015
Stephen L Sabba	director	DORSET MANAGEMENT CORP, 485 UNDERHILL BLVD SUITE 205, SYOSSET NY 11791
Mark Corrigan	director
Suzanne Louise Bruhn	director	C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746
John C Thomas	director	8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615
Murray Stewart	officer: Executive Vice President, R&D	C/O NOVELION THERAPEUTICS INC., 1800-510 WEST GEORGIA STREET, VANCOUVER A1 V6B OM3
Jason Aryeh	director	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Mary T Szela	director, officer: Chief Executive Officer	10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121